Fuda Cancer Hospital
Chief physician and professor. Grade 1 Expert at the Cancer Center, West China Hospital, Sichuan University (ranked No. 2 in China). Completed a postdoctoral fellowship in interventional radiology at the Chinese PLA General Hospital. Leads multidisciplinary team (MDT) care for complex tumors. Expert in minimally invasive interventional oncology for liver, lung, and pancreatic cancers.
Accreditations: Council Member, WATA. Member of CACA and CMDA committees on intervention, ablation, radioactive seeds, and pain. In 2023, inaugural director member, Palliative Care Committee, Sichuan MDA. Editorial board member of the Chinese Journal of Interventional Imaging and Therapy. Editorial board member of the Chinese Journal of Pain Medicine.
Leads 2 provincial S&T projects and 2 NSFC projects. Has 40+ papers, with 30+ as first or corresponding author. Highest impact factor: 10.73. Hepatocellular carcinoma (HCC) cohort: TACE + lenvatinib vs TACE + sorafenib. OS 18.97 vs 10.77 months. PFS 10.6 vs 5.4 months. ORR 66.8% vs 33.3%.
Dr. He Weibing is a pioneer of argon-helium cryoablation in China with more than 20 years of frontline practice. He was a founding member of Fuda Cancer Hospital (Guangzhou). He co-founded its Minimally Invasive Tumor Treatment Center and served as Executive Deputy Director. He also helped found the Ablation Group of the China Anti-Cancer Association. He has been the primary operator in more than 10,000 procedures.
He specializes in tumor cryoablation and is proficient in 125I seed brachytherapy, with a focus on liver and lung cancers. He proposed ten argon-helium techniques. Key co-authored data include: lung cryotherapy n=508; NSCLC n=120 (CR 25.5%, PR 41.8%, 6/12/24-month survival 64%/55%/36%); pancreatic cancer n=38 (median survival 12 months). He served on editorial boards in 2008 and 2010. He has been a national trainer for Varian and Boston Scientific since 2001.
Professor Luo Xiaoping is a nationally recognized interventional radiologist and a leading authority in Western China. He began pioneering vascular interventions in the early 1990s. He helped found the Interventional Group at the Second Affiliated Hospital of Chongqing Medical University.
He has completed over 100,000 interventional procedures, including about 4,000 complex cases. His key skills include TACE for hepatocellular carcinoma, Budd–Chiari interventions, TIPS, and single-stage bilateral stenting for hilar biliary obstruction, with success rates near 100%. He has been a master’s supervisor since 2007. He has trained many physicians, guided complex cases at more than 40 major hospitals across Western China, and helped build interventional programs. He has published 32 papers as first or corresponding author (22 CSCD core, 4 Chinese core, 6 CSCD extended).
Professor Xiao Yueyong is Chief Physician in the Department of Radiological Diagnosis at the Chinese PLA General Hospital. He is a leading expert in minimally invasive interventional oncology. He serves as the inaugural President of WATA (2025–). He is President of the International (2020–) and Asian (2012–) Societies of Cryotherapy. He is also Deputy Head of the NHC Expert Group on tumour ablation regulations (2009–).
He has performed over 100,000 CT/MRI‑guided minimally invasive procedures. His work covers chemical ablation, RFA, MWA, cryoablation, and NanoKnife (IRE). He introduced and advanced NanoKnife ablation in China. He led the first national standards for tumour cryoablation and NanoKnife.
Honors include the National Special Contribution Award (Lifetime Honorary). He received First Prize from the Chinese Medicine Education Association (2021). He received two Second Prizes for Military Medical Achievements (2016, 2018) and two Second Prizes from the China Anti‑Cancer Association (2019, 2022). He was named Asian Ablation Master. His research record includes 13 Chinese patents. He is the principal investigator for four NSFC projects and one MOST subject. He has published over 200 papers, with over 110 as first or corresponding author and over 40 in SCI journals. He has led over 10 ablation guidelines or consensus statements.
Lymphangioma is not cancer. It is a benign malformation of the lymphatic system. In China, clinicians confirm the diagnosis through high-resolution imaging and histopathology. Specialists use specific markers like D2-40 to rule out rare malignancies. This process ensures accurate treatment planning for fluid-filled cysts.
Bookimed Expert Insight: While lymphangioma is benign, its location near vital structures often requires specialized intervention. Facilities like Fuda Cancer Hospital in Guangzhou utilize vascular interventional therapy and minimally invasive cryosurgery. This is particularly valuable when the malformation is located near major blood vessels. Choosing a JCI-accredited facility ensures the pathology lab meets international standards for complex IHC staining.
Patient Consensus: Patients note it is important to seek specialists who regularly distinguish these growths from similar-sounding conditions. They emphasize that clear MRI results help manage the anxiety of waiting for biopsy confirmation.
China offers a multidisciplinary approach for lymphangioma treatment. Specialists use sclerotherapy as a first-line therapy for cystic lesions. Advanced facilities like Fuda Cancer Hospital employ minimally invasive technologies such as NanoKnife and cryosurgery. Surgical excision remains the definitive standard for microcystic cases.
Bookimed Expert Insight: Patient volume at specialized centers like Fuda Cancer Hospital exceeds 30,000 international cases. This high volume allows surgeons to master cryosurgery for lesions others might deem inoperable. Look for clinics with JCI accreditation to ensure safety protocols match global standards.
Patient Consensus: Patients emphasize that sclerotherapy often requiring multiple sessions and significant swelling is normal. They recommend verifying if a lesion is macrocystic or microcystic before choosing between surgery and injections.
Surgery offers lower recurrence rates for localized lymphangiomas but carries higher risks of nerve injury and scarring. Chinese centers report surgical recurrence rates under 10% for well-defined lesions. In contrast, sclerotherapy recurrence can exceed 50% for larger vessels though it involves significantly less procedural pain.
Bookimed Expert Insight: While surgery seems definitive, Fuda Cancer Hospital in Guangzhou specializes in vascular interventional therapies for complex cases. Our data shows JCI-accredited facilities often use interventional techniques when lesions are near vital nerves. This approach prioritizes functional safety over the aggressive removal seen in traditional open surgery.
Patient Consensus: Patients note that surgery feels more final for well-defined lesions but worry about visible scarring. Many highlight that sclerotherapy often requires multiple sessions and causes temporary swelling before the lesion begins to shrink.
China leading hospitals for lymphangioma care include Shanghai Ninth People Hospital and Beijing Children Hospital. These centers specialize in vascular malformations. They use sclerotherapy and micro-resection. Facilities in Beijing, Shanghai, and Guangzhou offer multidisciplinary teams. These teams include pediatric surgeons and interventional radiologists.
Bookimed Expert Insight: While university hospitals in Shanghai and Beijing are famous for volume, Fuda Cancer Hospital in Guangzhou offers a distinct advantage for international patients through its JCI accreditation and experience treating people from over 100 countries. This global focus often translates into smoother logistics and more robust support for non-residents compared to strictly public institutions.
Patient Consensus: Patients emphasize that treating lymphangiomas near the neck or airway requires a team with strong pediatric anesthesiology and ICU backup. Many note that combined approaches using both sclerotherapy and surgery often provide better long-term results than surgery alone.
Recurrence is not inevitable following lymphangioma treatment. Success depends heavily on the lesion architecture and treatment method chosen. Complete surgical excision offers the lowest recurrence rate of 11% to 17%. Conversely, simple aspiration almost always leads to regrowth because the underlying malformed vascular lining remains intact.
Bookimed Expert Insight: While many associate lymphangioma care with pediatric centers, JCI-accredited oncology hospitals like Fuda Cancer Hospital in Guangzhou apply advanced interventional therapies. Their expertise in vascular interventional therapy and cryosurgery is often reserved for complex adult cases. This is significant because specialized interventional approaches can stabilize lesions that were previously considered too infiltrative for standard surgery.
Patient Consensus: Patients note that recurrence isn't automatic, especially when lesions are treated early. Many emphasize that swelling after treatment can sometimes be simple inflammation or infection rather than true regrowth.
Chinese hospitals provide extensive pediatric expertise for international children through specialized private networks and elite public international departments. Facilities in major cities like Beijing and Guangzhou offer Western-trained doctors and JCI-accredited care. Specialized pediatric oncology and vascular anomaly teams treat complex conditions like lymphangioma using advanced techniques.
Bookimed Expert Insight: While many search for oncology generally, our data shows that specialized centers like Fuda Cancer Hospital in Guangzhou serve patients from over 100 countries. This high international volume is a key quality signal for rare pediatric conditions. Expert surgeons like Prof. Liu Shi Xin at Xiamen Humanity Hospital hold dual expertise in pediatric oncology and precision radiotherapy. This cross-specialty knowledge is vital for complex lymphangiomas that may require multidisciplinary management beyond simple surgery.
Patient Consensus: Parents emphasize that finding a team with specific pediatric vascular anomaly experience is more important than general surgical availability. They note it is critical to confirm the hospital has pediatric airway backup for lesions located in the neck or oral cavity.